Latest Athersys Inc. Stories
Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStemÂ®, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.
CLEVELAND, Jan. 24, 2011 /PRNewswire/ -- Athersys, Inc. (Nasdaq: ATHX), a clinical stage biopharmaceutical company, today announced that its January 11th Retail Investor Conferences.com presentation is available for on-demand viewing.
Case Western Reserve University School of Medicine and Athersys, Inc. (NASDAQ: ATHX) announced a joint scientific study on spinal cord injury will be published today in the January issue of the Journal of Neuroscience.
CLEVELAND, Jan. 7, 2011 /PRNewswire/ -- Athersys, Inc. (Nasdaq: ATHX) today announced that its CEO, Dr. Gil Van Bokkelen Ph.D., will present at Retail Investor Confrences.com.
VANCOUVER, July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc.
Athersys, Inc announced today that it has entered into an agreement with Pfizer Inc to develop and commercialize MultiStem for the treatment of Inflammatory Bowel Disease.
Funding supports multiple commercial, emerging and pilot projects CLEVELAND, June 25 /PRNewswire-USNewswire/ -- The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University (CWRU), Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc.
CLEVELAND, Nov. 12, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced the achievement of another clinical development milestone related to its discovery alliance with Bristol-Myers Squibb Company (NYSE:BMY).
CLEVELAND, Ohio, Nov. 10, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its results for the quarter ended September 30, 2008 and provided an update on key clinical development programs, including ATHX-105 and MultiStem.
CLEVELAND, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced the presentation of data from its ongoing phase I clinical trial of MultiStem(r) for individuals following acute myocardial infarction (AMI).
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.